UBS raised the firm’s price target on Certara to $20 from $17 and keeps a Neutral rating on the shares. The firm believes that a return to double digit sales growth will likely be elongated due to biopharma end market headwinds, and Q4 results and FY24 guidance support the thesis, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CERT:
- Certara Reports Fourth Quarter 2023 Financial Results
- Certara initiated with a Market Perform at Leerink
- Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
- Certara price target raised to $18 from $16 at Barclays
